The global drug-device combination products market was estimated to be worth US$ 123.5 billion in 2020 and is forecast to grow at a CAGR of 8.2% between now and 2027. The new combination products entering the market don’t just include traditional parenterals, but autoinjectors and inhalers too, as well as other next generation devices. Nadine Kasidas-Neale at Recipharm explains the incoming changes to EU medical device regulations and their impact on pharmaceutical companies developing drug delivery devices, including autoinjectors for the EU market.